Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial

The Lancet Neurology

Volumn 7, Issue 4, 2008, Pages 299-309

  Davis, Stephen M ^a   Donnan, Geoffrey A ^a   Parsons, Mark W ^b   Levi, Christopher ^b   Butcher, Kenneth S ^c   Peeters, Andre ^d   Barber, P Alan ^e   Bladin, Christopher ^f   De Silva, Deidre A ^a   Byrnes, Graham ^a   Chalk, Jonathan B ^g   Fink, John N ^h   Kimber, Thomas E ⁱ   Schultz, David ^j   Hand, Peter J ^a   Frayne, Judith ^k   Hankey, Graeme ^l   Muir, Keith ^m   Gerraty, Richard ^k   Tress, Brian M ^a   Desmond, Patricia M ^a   more..

^a UNIVERSITY OF MELBOURNE   (Australia)

^b JOHN HUNTER HOSPITAL   (Australia)

^c UNIVERSITY OF ALBERTA   (Canada)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

^f Eastern Melbourne Neurosciences   (Australia)

^g ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^h UNIVERSITY OF OTAGO   (New Zealand)

ⁱ ROYAL ADELAIDE HOSPITAL   (Australia)

^j FLINDERS MEDICAL CENTRE   (Australia)

^k ALFRED HOSPITAL   (Australia)

^l ROYAL PERTH HOSPITAL   (Australia)

^m SOUTHERN GENERAL HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; GADOLINIUM; PLACEBO;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; CAREGIVER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DOUBLE BLIND PROCEDURE; ECHO PLANAR IMAGING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERFUSION WEIGHTED IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPERFUSION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; DRUG EVALUATION; ECHO-PLANAR IMAGING; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 40949161352     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70044-9     Document Type: Article

References (39)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
2. Wahlgren N., Ahmed N., Davalos A., et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369 (2007) 275-282
3. Hacke W., Donnan G., Fieschi C., et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
4. Symon L. Recovery of brain function after ischaemia. Acta Neurochir Suppl (Wien) 41 (1987) 97-103
5. Darby D., Barber P., Gerraty R., et al. Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI. Stroke 30 (1999) 2043-2052
6. Rother J., Schellinger P., Gass A., et al. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours. Stroke 33 (2002) 2438-2445
7. Lansberg M., O'Brien M., Tong D., Moseley M., and Albers G. Evolution of cerebral infarct volume assessed by diffusion-weighted magnetic resonance imaging. Arch Neurol 58 (2001) 613-617
8. Parsons M., Barber P., Chalk J., et al. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 51 (2002) 28-37
9. Warach S., Gaa J., Siewert B., Wielopolski P., and Edelman R. Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. Ann Neurol 37 (1995) 231-241
10. Barber P., Darby D., Desmond P., et al. Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI. Neurology 51 (1998) 418-426
11. Butcher K., Parsons M., Baird T., et al. Perfusion thresholds in acute stroke thrombolysis. Stroke 34 (2003) 2159-2164
12. Davis S., Donnan G., Butcher K., and Parsons M. Selection of thrombolytic therapy beyond 3 h using magnetic resonance imaging. Curr Opin Neurol 18 (2005) 47-52
13. Butcher K., Parsons M., MacGregor L., et al. Refining the perfusion-diffusion mismatch hypothesis. Stroke 36 (2005) 1153-1159
14. Hacke W., Kaste M., Fieschi C., et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274 (1995) 1017-1025
15. Adams Jr. H., del Zoppo G., Alberts M., et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 38 (2007) 1655-1711
16. EPITHET: Echoplanar Imaging Thrombolysis Evaluation Trial. Available at http://www.strokecenter.org/trials/trialDetail.aspx?tid=420&search_s tring=epithet (accessed Jan 18, 2008).
17. Ostergaard L., Weisskoff R., Chesler D., Gyldensted C., and Rosen B. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med 36 (1996) 715-725
18. Barber P., Parsons M., Desmond P., et al. The use of PWI and DWI measures in the design of "proof-of-concept" stroke trials. J Neuroimaging 14 (2004) 123-132
19. Hacke W., Albers G., Al-Rawi Y., et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36 (2005) 66-73
20. Albers G., Thijs V., Wechsler L., et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 60 (2006) 508-517
21. Warach S. New imaging strategies for patient selection for thrombolytic and neuroprotective therapies. Neurology 57 (2001) S48-S52
22. Phan T., Donnan G., Davis S., and Byrnes G. Proof-of-principle phase II MRI studies in stroke: sample size estimates from dichotomous and continuous data. Stroke 37 (2006) 2521-2525
23. Furlan A., Eyding D., Albers G., et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 37 (2006) 1227-1231
24. Ringelstein E., Biniek R., Weiller C., Ammeling B., Nolte P., and Thron A. Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology 42 (1992) 289-298
25. Schellinger P., Jansen O., Fiebach J., et al. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI. Stroke 31 (2000) 1318-1328
26. Schellinger P., Fiebach J., Jansen O., et al. Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia. Ann Neurol 49 (2001) 460-469
27. Furlan A., Higashida R., Wechsler L., et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. JAMA 282 (1999) 2003-2011
28. Molina C., Montaner J., Abilleira S., et al. Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study. Stroke 32 (2001) 2821-2827
29. Thomalla G., Sobesky J., Kohrmann M., et al. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke 38 (2007) 313-318
30. Neumann-Haefelin T., Wittsack H., Wenserski F., et al. Diffusion- and perfusion-weighted MRI. The DWI/PWI mismatch region in acute stroke. Stroke 30 (1999) 1591-1597
31. European Stroke Conference (Glasgow, United Kingdom 2007) Highlights. http://eurostroke.com/esc_gla_highlights.htm (accessed Jan 17, 2008).
32. Thomalla G., Schwark C., Sobesky J., et al. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke 37 (2006) 852-858
33. Schellinger P., Thomalla G., Fiehler J., et al. MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients. Stroke 38 (2007) 2640-2645
34. Kohrmann M., Juttler E., Fiebach J., et al. MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol 5 (2006) 661-667
35. MR RESCUE: MR and Recanalization of Stroke Clots Using Embolectomy. http://www.strokecenter.org/trials/TrialDetail.aspx?tid=559 (accessed Jan 18, 2008).
36. Kane I., Carpenter T., Chappell F., et al. Comparison of 10 different magnetic resonance perfusion imaging processing methods in acute ischemic stroke: effect on lesion size, proportion of patients with diffusion/perfusion mismatch, clinical scores, and radiologic outcomes. Stroke 38 (2007) 3158-3164
37. Kane I., Sandercock P., and Wardlaw J. Magnetic resonance perfusion diffusion mismatch and thrombolysis in acute ischaemic stroke: a systematic review of the evidence to date. Neurol Neurosurg Psychiatry 78 (2007) 485-491
38. The Third International Stroke Trial. Available at http://www.strokecenter.org/trials/TrialDetail.aspx?tid=81 (accessed Jan 18, 2008).
39. ECASS-III: Placebo controlled trial of alteplase (rt-PA) in acute ischemic hemispheric stroke where thrombolysis is initiated between 3 and 4 hours after stroke onset. Available at http://www.strokecenter.org/trials/TrialDetail.aspx?tid=475 (accessed Jan 18, 2008).